Clinical trials: Proton Pump Inhibitor
Gastroesophageal Reflux
Comparison of Vonoprazan to Esomeprazole in Participants With Symptomatic GERD Who Responded Partially to a High Dose of Proton Pump Inhibitor (PPI)
The purpose of this study is to determine the effect of vonoprazan compared to esomeprazole for preventing heartburn symptoms over a 4-week treatment period in participants who have a partial response to treatment with…
- Trial name
- NCT02743949
- Testing
- Vonoprazan, Esomeprazole
- Where
- 39 sites in Belgium, Bulgaria and 4 more
- Volunteers
- 256 people
- Sponsor
- Takeda
Gastroesophageal Reflux Disease
A Trial of IW-3718 for 8 Weeks in Patients With Symptomatic Gastroesophageal Reflux Disease (GERD)
The objectives of this study are to evaluate the safety, efficacy, and dose-response relationship of IW-3718 administered orally to participants who have GERD and continue to experience GERD symptoms while receiving once-daily…
- Trial name
- NCT02637557
- Testing
- IW-3718, PPI
- Where
- 62 sites in United States
- Volunteers
- 282 people
- Sponsor
- Ironwood Pharmaceuticals, Inc.
Type 1 Diabetes
Incretin Effect and Use After Clinical Islet Transplantation
We aim to study if the administration of medications to increase the secretion of hormones from the intestines can improve glycemic control, reduce insulin use and promote β-cell regeneration/expansion in subjects with type 1…
- Trial name
- NCT00768651
- Testing
- Pantoprazole, Sitagliptin
- Where
- Canada
- Volunteers
- 8 people
- Sponsor
- University of Alberta
Helicobacter Pylori Infection
Comparison of 12-day Reverse Hybrid Therapy and 12-day Standard Triple Therapy for Helicobacter Pylori Infection
Reverse hybrid therapy is a one-step two-phase treatment for Helicobacter pylori infection with less cost than standard triple therapy.
- Trial name
- REHYTRI (NCT02359435)
- Testing
- Reverse hybrid therapy, Standard triple therapy
- Where
- Taiwan
- Volunteers
- 440 people
- Sponsor
- Kaohsiung Veterans General Hospital.
Non-erosive Gastroesophageal Reflux Disease
A Study of E3810 With Pre- and Post-Treatment pH Monitoring in Patients With Non-Erosive Gastroesophageal Reflux Disease
To investigate esophageal reflux condition in patients with non-erosive gastroesophageal reflux disease by assessing with a 24-hour esophageal pH monitoring or effects of a 4-week treatment with 5 mg/day or 10 mg/day of E3810…
- Trial name
- NCT00165672
- Testing
- RABEPRAZOLE SODIUM
- Where
- 13 sites in Japan
- Volunteers
- 26 people
- Sponsor
- Eisai Inc.
Barretts Esophagus With Dysplasia
The Impact of Adjuvant Liquid Alginate on Endoscopic Ablation Therapy of Complicated Barrett's Esophagus
This study evaluates the addition of an alginate based solution to twice daily proton pump inhibitor therapy (PPI) in patients undergoing ablative therapy for dysplastic Barrett's esophagus.
- Trial name
- NCT03193216
- Testing
- Alginates
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Medical University of South Carolina
Healthy Volunteers
Study of the Effect of Food and a Proton Pump Inhibitor (PPI; Omeprazole) on LOXO-305 in Healthy Participants
The main purpose of this study is to learn about how food and a PPI (omeprazole) affect LOXO-305 in healthy participants. Participation could last about nine weeks.
- Trial name
- NCT05134350
- Testing
- LOXO-305, Omeprazole
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Loxo Oncology, Inc.
Hypothyroidism;Postablative
Levothyroxine Sodium in Thyroidectomized Patients Taking Proton Pump Inhibitors
This is an open-label therapeutic efficacy study of Tirosint (levothyroxine sodium) capsules in thyroidectomized patients taking proton pump inhibitors and levothyroxine, evaluating changes in serum levels of Thyroid Stimulating…
- Trial name
- NCT03094416
- Testing
- levothyroxine sodium capsule, Proton pump inhibitor (PPI), Levothyroxine Sodium (LT4) Tablets
- Where
- 9 sites in United States
- Volunteers
- 66 people
- Sponsor
- IBSA Institut Biochimique SA
Pancreatic Cancer, Pancreas Cancer
Role of Proton Pump Inhibitors on the Postoperative Course Following Pancreaticoduodenectomy
The purpose of this study is to prospectively determine the effects of administering proton pump inhibitors (PPIs) following pancreaticoduodenectomy on postoperative outcomes.
- Conditions
- Pancreatic Cancer, Pancreas Cancer, Ampullary Cancer, Pancreas Neuroendocrine Tumor
- Trial name
- NCT05251233
- Testing
- Pantoprazole
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- Washington University School of Medicine
Healthy Volunteers
Drug Interaction With Proton Pump Inhibitors for Nifedipine ER Tablets
The purpose of this study is to measure the amount of study drug present in blood after being administered a generic version of nifedipine extended-release tablets, 60 mg (Valeant Pharmaceuticals, LLC) and brand-name version…
- Trial name
- NCT03100838
- Testing
- Nifedipine 60 MG Extended Release Oral Tablet, omeprazole/sodium bicarbonate, SmartPill (TM)
- Where
- United States
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Food and Drug Administration (FDA)
Healthy
Study of H2 Antagonist and a Proton Pump Inhibitor of Selpercatinib in Healthy Participants
The main purpose of this study is to learn about how H2 antagonist (ranitidine) and proton pump inhibitor (PPI) (omeprazole) affect Selpercatinib in healthy participants.
- Trial name
- NCT05338502
- Testing
- Selpercatinib, Ranitidine, Omeprazole
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Helicobacter Pylori Infection
13-C Urea Breath Test Using BreathID System and PPIs (Proton Pump Inhibitors)
Approximately 200 patients with suspected H.pylori will be tested with a 13C-Urea Breath Test (UBT) to ascertain H.pylori positive.
- Trial name
- NCT00825630
- Testing
- Lansoprazole (Lanton), Omeprezole (Losec), Pantoprazole(Controloc)
- Where
- Israel
- Volunteers
- 123 people
- Sponsor
- Meridian Bioscience, Inc.
Gastroesophageal Reflux
Fexofenadine Use in Gastroesophageal Reflux Symptoms
The investigators wish to study the effectiveness of Fexofenadine (an over the counter allergy pill) for the treatment of gastroesophageal reflux symptoms in patients who still have symptoms despite being on a proton pump…
- Trial name
- NCT03425097
- Testing
- Fexofenadine
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Stanford University
Gastroesophageal Reflux Disease (GERD)
Trial of IW-3718 for 8 Weeks in Patients With Persistent Gastroesophageal Reflux Disease (GERD) Receiving Proton Pump Inhibitors (PPIs)
The objective of this study is to evaluate the safety and efficacy of IW-3718 administered to patients with GERD who continue to have persistent symptoms, such as heartburn and regurgitation, while receiving once-daily (QD)…
- Trial name
- NCT03561883
- Testing
- IW-3718, Standard-dose PPIs QD
- Where
- 101 sites in United States, Canada
- Volunteers
- 609 people
- Sponsor
- Ironwood Pharmaceuticals, Inc.
Healthy
SSP-002358 Drug Interaction Study With Omeprazole
This is a drug interaction study evaluating whether blood plasma concentrations of SSP-002358-base are altered when SSP-002358 is taken together with omeprazole.
- Trial name
- NCT01415349
- Testing
- SSP-002358, SSP-002358 + omeprazole
- Where
- Netherlands
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Shire
Gastroesophageal Reflux, Chronic Obstructive Pulmonary Disease
COPD Patients Diagnosed With GERD,COPD Exacerbations After Treatment With High Dose PPI
The purpose of this study is to determine which COPD patients have GERD and if COPD patients with GERD treated with high dose lansoprazole for 1 year decreases the frequency of COPD exacerbations compared to the previous year…
- Trial name
- GERD/COPD (NCT00523367)
- Testing
- 24 hour pH testing
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- University of Florida
Gastroesophageal Reflux Disease (GERD)
Symptom Improvements in Gastroesophageal Reflux Disease (GERD) Patients
The purpose of this study is to estimate the effect of AZD3355 as an add-on treatment to a Proton Pump Inhibitor (PPI) on Gastroesophageal reflux disease (GERD) symptoms in patients with an incomplete response to PPI treatment.
- Trial name
- NCT00394472
- Testing
- AZD3355
- Where
- 38 sites in Australia, Belgium and 6 more
- Volunteers
- 244 people
- Sponsor
- AstraZeneca
Upper Gastrointestinal Bleeding
Anticoagulation With Enhanced Gastrointestinal Safety (AEGIS) Trial
This is a pragmatic, single center, feasibility pilot cluster randomized trial with embedded individual randomization to evaluate implementation strategies to increase the use of evidence-based practices to reduce upper…
- Trial name
- AEGIS (NCT05085405)
- Testing
- Clinician notification, Clinician Notification with Nurse Facilitation, Clinician Notification / Patient Activation
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- University of Michigan
Gastroesophageal Reflux Disease
An Explorative Trial to Evaluate the Pharmacodynamic Effect of SPD557 on Reflux Parameters in Refractory GERD Patients
The purpose of this trial is to investigate the pharmacodynamic effect on reflux parameters of SPD557 tablets (0.5 mg t.i.d., on top of PPI treatment) in patients with Gastroesophageal Reflux Disease (GERD) with persistent…
- Trial name
- NCT01370863
- Testing
- SPD557
- Where
- 15 sites in Belgium, France and 4 more
- Volunteers
- 67 people
- Sponsor
- Shire
Hepatic Encephalopathy
Deprescribing Proton Pump Inhibitors to Reduce Post-TIPS Hepatic Encephalopathy
A total of 40 patients taking proton pump inhibitors (PPIs) who undergo transjugular intrahepatic portosystemic shunt (TIPS) creation as part of routine clinical care will be randomized in 1:1 fashion to either continue or…
- Trial name
- NCT05070351
- Testing
- PPI deprescribing
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Duke University